IRVINE, Calif. and HERSTAL, Belgium, Oct. 16, 2013 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext:MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the company’s MGMT (O6-methylguanine-DNA methyl transferase) test, PredictMDx(TM) for Glioblastoma, used to identify patients most likely to respond to targeted therapy, has been included in the 2013 National Comprehensive Cancer Network (NCCN) Guidelines. The NCCN is an alliance of 23 world-leading cancer centers. The new guidelines are published online at www.nccn.org.
Help employers find you! Check out all the jobs and post your resume.
